Myasthenia Gravis Therapeutic Pipeline Drugs and Companies Review H2 2014 Report at RnRMarketReserach.com

USA - English

• USA - English

Dallas, TX (PRWEB) December 16, 2014 -- The report "Myasthenia Gravis Pipeline Review H2 2014" provides comprehensive information on the therapeutic development for Myasthenia Gravis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myasthenia Gravis and special features on late-stage and discontinued projects. Myasthenia gravis is an either auto-immune or genetic neuromuscular illness that results in varying muscular weak point and fatigue. Complete Report is Available @ http://www.rnrmarketresearch.com/myasthenia-gravis-pipeline-review-h2-2014-market-report.html .

Companies discussed in this Myasthenia Gravis Pipeline Review H2 2014 report include Alexion Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Astellas Pharma Inc., Biokine Therapeutics Ltd., CuraVac, Inc., Cytokinetics, Inc., GlaxoSmithKline plc, Grifols, S.A., HanAll Biopharma Co., Ltd., Neurotune AG, Pfizer Inc., Regenesance BV, Toleranzia AB.

Drugs profile discussed in this Myasthenia Gravis Pipeline Review H2 2014 report include ALN-CC5, belimumab, BKT-130, CK-2066260, eculizumab, GL-2045, HL-161, immune globulin, NT-1654, Recombinant Coversin, Recombinant Protein for Myasthenia Gravis, Regenemab, tacrolimus, tirasemtiv, Vaccine for Myasthenia Gravis, Vaccine for Myasthenia Gravis. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=250200 .

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global therapeutic landscape of Myasthenia Gravis
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Myasthenia Gravis and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Myasthenia Gravis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Myasthenia Gravis pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Inquire for Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=250200 . (This is a premium report priced at US$2000 for a single user License.)

Major points in Table of Content
List of Tables
Number of Products under Development for Myasthenia Gravis, H2 2014
Number of Products under Development for Myasthenia Gravis - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Products under Investigation by Universities/Institutes, H2 2014
Myasthenia Gravis - Pipeline by Alexion Pharmaceuticals, Inc., H2 2014
Myasthenia Gravis - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2014
Myasthenia Gravis - Pipeline by Astellas Pharma Inc., H2 2014
Myasthenia Gravis - Pipeline by Biokine Therapeutics Ltd., H2 2014
Myasthenia Gravis - Pipeline by CuraVac, Inc., H2 2014
Myasthenia Gravis - Pipeline by Cytokinetics, Inc., H2 2014
Myasthenia Gravis - Pipeline by GlaxoSmithKline plc, H2 2014
Myasthenia Gravis - Pipeline by Grifols, S.A., H2 2014
Myasthenia Gravis - Pipeline by HanAll Biopharma Co., Ltd., H2 2014
Myasthenia Gravis - Pipeline by Neurotune AG, H2 2014
Myasthenia Gravis - Pipeline by Pfizer Inc., H2 2014
Myasthenia Gravis - Pipeline by Regenesance BV, H2 2014
Myasthenia Gravis - Pipeline by Toleranzia AB, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Myasthenia Gravis Therapeutics - Recent Pipeline Updates, H2 2014
Myasthenia Gravis - Dormant Projects, H2 2014
Myasthenia Gravis - Discontinued Products, H2 2014

List of Figures
Number of Products under Development for Myasthenia Gravis, H2 2014
Number of Products under Development for Myasthenia Gravis - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Products, H2 2014
Assessment by Monotherapy Products, H2 2014

Explore more reports on Autoimmune Drugs industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/autoimmune-drugs .

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Ritesh Tiwari, RnR Market Research, http://www.rnrmarketresearch.com/, +1 (888) 391-5441, [email protected]